Tofacitinib [477600-75-2]

Catalog number: AG-CR1-3625-M025
Brand: AdipoGen Life Sciences
Packing: 25 mg
Other sizes: Other size available
Price: € 175.00
Expected delivery time: 7 days
Quantity:
Chemical Structure
Chemical Structure...

Product specifications for - Tofacitinib [477600-75-2]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 477600-75-2
Properties: 
Purity: >98%
Molecular Formula: C16H20N6O
Molecular weight: 312.4
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Storage instructions: 2-¦C to 8-¦C, -20-¦C
Scientific information: 
Scientific info: Chemical. CAS: 477600-75-2. Formula: C16H20N6O. MW: 312.4. Potent cell permeable JAK3 inhibitor (IC50 = 1nM). Shows also JAK-1 inhibitory activity. Immunosuppressive and anti-inflammatory agent. Inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Blocks downstream STAT signaling, resulting in potent inhibition of several cytokines, including interleukins 2, 4, 7, 9, 15 and 21, which are integral to lymphocyte activation, function and proliferation. Investigated for several autoimmune disorders including, rheumatoid arthritis and psoriasis. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. - Potent cell permeable JAK3 inhibitor (IC50 = 1nM). Shows also JAK-1 inhibitory activity. Immunosuppressive and anti-inflammatory agent. Inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Blocks downstream STAT signaling, resulting in potent inhibition of several cytokines, including interleukins 2, 4, 7, 9, 15 and 21, which are integral to lymphocyte activation, function and proliferation. Investigated for several autoimmune disorders including, rheumatoid arthritis and psoriasis. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro.
Safety information: 
ADR klasse: 6.1
UN Number: UN 2811
MSDS: MSDS
Hazard information: Danger, Excepted quantity
Additional information: 
Synonyms: AG-CR1-3625-M025
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor: P.S. Changelian, et al.; Science 302, 875 (2003) Read more
Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates: D.C. Borie, et al.; Transplantation 79, 791 (2005) Read more
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates: D.C. Borie, et al.; Transplantation 80, 1756 (2005) Read more
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia: E. Kudlacz, et al.; Eur. J. Pharmacol. 582, 154 (2008) Read more
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders: K. West; Curr. Opin. Investig. Drugs 10, 491 (2009) (Review) Read more
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection: M.E. Flanagan, et al.; J. Med. Chem. 53, 8468 (2010) Read more
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP: W. Ju, et al.; Blood 117, 1938 (2011) Read more
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550): K. Ghoreschi, et al.; J. Immunol. 186, 4234 (2011) Read more
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production: K. Migita, et al.; BMC Immunol. 12, 51 (2011) Read more
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical: Y. Tanaka & K. Yamaoka; Mod. Rheumatol. 23, 415 (2013) (Review) Read more